Trellis Vitality Review: $150 Semaglutide

Trellis Vitality does one thing better than any other provider in the batch of seven we screened in August 2026, and one thing conspicuously worse. The good half is its GLP-1 pricing, which is a plain published table with a month-to-month column that says what it is. The bad half is everything else it sells, where the price surface stops at the word "starting".

The table

Semaglutide is $150 a month on a single-month plan, $140 on three months and $133 on six. Tirzepatide is $199, $189 and $179 across the same three columns. The page labels these as per-month prices with longer plans costing less per month, and states that all dosages are available at the same price.¹

Read that structure carefully, because it is the shape we spend most of our time correcting elsewhere. The one-month column is explicitly the month-to-month rung — it is not a total divided by twelve, not an annual commitment wearing a monthly label, and not a first-order promotion. The discount for committing six months is about twelve percent, which is a real discount rather than the kind that only exists because the short plan was inflated to create it. Of the seven providers in this batch, this is the best-formed GLP-1 ladder we found.

$150 puts Trellis in the honest middle of what compounded GLP-1 costs per month, and $199 tirzepatide is competitive enough to matter on our tirzepatide ruling. Both molecules on one account, priced flat across the dose range, is a combination worth having — and the difference between the two molecules, which is the choice that decides which column you are reading, is set out in semaglutide vs tirzepatide.

Then the pricing stops

Trellis runs four other programs: NAD+, which it treats as its flagship, glutathione, Lipo-MIC with B12, and tesamorelin. For all four, the site publishes a single "starting at" figure and nothing else. NAD+ starts at $129 a month, glutathione at $93, Lipo-MIC and B12 at $130, tesamorelin at $299.

Those are not monthly prices and we are not going to print them as though they were. A "starting at" number with no rung table behind it tells you the floor of a ladder whose shape you cannot see. We looked for the rest of it — the product pages, the site's own build output, the intake flow — and there is no table anywhere. Given the GLP-1 page discounts its six-month column by roughly twelve percent, it is a reasonable guess that these four figures are the longest-prepay rungs and that the month-to-month price is higher. A reasonable guess is not an observation, and we are recording it as unverified rather than publishing it.

If you want one of those four programs, the honest way to state what Trellis costs is: from $129 a month for NAD+, full ladder not published. Ask what one month costs before you enrol.

A claim the site makes about itself

Trellis's own blog states, twice in one article, that the company publishes complete pricing on its program pages.² It does not. The GLP-1 page does; the other four do not, and the difference is a whole ladder.

We flag that because it is the sort of thing a reader takes on trust and never checks, and because it changes what a "starting at" figure means. A company that says it publishes everything, and then publishes a floor, is not making a neutral omission. Price honesty is one of the two heaviest factors in how we grade a provider for precisely this reason — a gap in a price surface costs more than a high price does.

The same instinct applies to the marketing furniture on Trellis's pages. There is a star rating, a current-patient count, an average-time-saved claim and an average-annual-savings claim. None of the four is sourced anywhere on the site — no methodology, no sample, no date. We are not repeating those numbers, and neither should any board that lists this provider.

Who is behind the prescription

The medical group is Arora Health & Aesthetics, LLC, whose medical director is Dr. Sean Arora, NPI 1841729449, verified as an active Family Medicine record in the national registry.³ The compounding pharmacy is VialsRX, in Houston, Texas, named outright — good practice, and something most of this cohort does not do at all. Trellis claims all 50 states.

That medical group should look familiar. It is the same one behind The Edit, and the same medical director. The two companies have different pharmacies, different prices and genuinely different catalogues, so they are separable products. What they are not is two independent clinical opinions, and if you are shortlisting both because you want a second one, you are not getting it.

One gap worth naming: Trellis does not publish a legal entity. Its terms page is roughly three kilobytes of text and names no LLC or corporation as the operator. Its promise of no membership fee, no consult cost and a free assessment is made in marketing copy and is not corroborated in any terms document — which is not the same as being false, but it is the difference between a policy and a slogan.

We screened the trading name, the medical group and the pharmacy against the FDA's live warning-letter index and found no company-column match.⁴ The pass carried a control — an unrelated telehealth seller with a real February 2026 letter — which returned correctly every time, so the zero is a result rather than a broken query.

The ruling

For compounded semaglutide or tirzepatide, Trellis Vitality is one of the two or three cleanest buys among the seven we screened: a real table, a real month-to-month rung, a named pharmacy, a verifiable medical director. For NAD+ or any of the other three programs, it is a provider you cannot price, and you should not enrol until you have asked what month one actually costs. Put it beside Auren Rx, which publishes both a subscription and a no-commitment rung for every single item it sells, and beside the rest of our ranked verdicts.